CN Mobile Logo

Search form


Benefit of adjuvant RT/CT for pancreatic ca affirmed

Benefit of adjuvant RT/CT for pancreatic ca affirmed

LOS ANGELES—Patients who undergo complete resection of invasive adenocarcinoma of the pancreas are roughly two-thirds more likely to be alive at 5 years if they receive adjuvant chemotherapy and radiation therapy, compared with no adjuvant therapy, according to the 30-year Mayo Clinic experience.

[Editor's note: This study included some of the Mayo Clinic patients in the collaborative trial reported on page 1, but this population was unique in that all patients underwent R0 resections.]

"Even with optimal surgical resection, only about 10% to 20% of patients remain alive at 5 years," lead author Michele M. Corsini, MD, said at ASTRO 2007 (abstract 138). "Several multicenter trials have been performed looking at adjuvant therapy to improve patient outcomes after surgery, but inconsistent results and trial design critiques have led to controversy over its role."

To assess the impact of adjuvant therapy on survival and to identify prognostic factors, the investigators retrospectively studied 472 patients who underwent potentially curative resection for invasive pancreatic carcinoma at the Mayo Clinic between 1975 and 2005, with negative margins (R0) and T1-3, N0-1, M0 disease. Patients were excluded if they had indolent tumors or died within 30 days of surgery.

In terms of adjuvant therapy, 39% of patients had observation alone, whereas 59% received chemoradiation (usually alone, but occasionally followed by more chemotherapy), and 2% received chemotherapy alone, Dr. Corsini said.

For the entire cohort, median overall survival was 1.8 years, and 5-year overall survival was 23%. In univariate analyses, median overall survival was significantly poorer for patients with T3 vs T1-2 disease (1.6 vs 2.1 years), N1 vs N0 disease (1.5 vs 2.6 years), and high-grade vs low-grade disease (1.4 vs 2.6 years). In addition, median survival decreased significantly as the number of these adverse prognostic factors increased, from 0 to 1 to 2 (3.4, 1.9, and 1.3 years). In multivariate analyses, nodal status and grade independently predicted survival.


Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.